2 weeks Ago By Defense World Staff
Equities researchers at StockNews.com began coverage on shares of Trevena ( NASDAQ:TRVN – Get Free Report ) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Stock Up 2.3 % Shares of Trevena stock opened at $3.98 on Friday.
Trevena has a 52-week low of $3.35 and a 52-week high of $25.75.
The firm’s 50 day moving average price is $3.08 and its 200-day moving average price is $1.31.
The company has a market cap of $3.38 million, a P/E ratio of -1.49 and a beta of 1.
03. Trevena ( NASDAQ:TRVN – Get Free Report ) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.
01) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36.
The business had revenue of $0.33 million during the quarter. As a group, equities research analysts forecast that Trevena will post -32.
25 EPS for the current fiscal year. Institutional Trading of Trevena Trevena Company Profile ( Get Free Report ) Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Stories Five stocks we like better than Trevena Want to Profit on the Downtrend? Downtrends, Explained. CarMax’s Impressive Rally: What Investors Should Watch Next How the NYSE and NASDAQ are Different, Why That Matters to Investors MarketBeat Week in Review – 9/23 – 9/27 What is the Nikkei 225 index? Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter .
.
